Vonoprazan-based triple tx feasible for H. pylori
(HealthDay)—The potassium-competitive acid blocker vonoprazan-based triple therapy seems safe and effective compared with conventional proton pump inhibitor (PPI)-based triple therapy as first-line treatment against Helicobacter pylori, according to a study published online Aug. 17 in the Journal of Digestive Diseases.
Satoki Shichijo, M.D., Ph.D., from the University of Tokyo, and colleagues performed a multicenter study involving 2,715 patients who received first-line H. pylori eradication therapy. Vonoprazan-based triple therapy was compared with conventional PPI-based triple therapy.
The researchers found that eradication rates were 87.2 and 72.4 percent for vonoprazan-based and conventional PPI-based therapy, respectively (P < 0.01). There were 10 cases of diarrhea, six of nausea/vomiting, and five of rash in the vonoprazan-based therapy group; these rates were not higher than those in the conventional PPI-based group.
"Vonoprazan-based triple therapy is feasible; it showed a higher eradication rate than conventional PPIs as a first-line regimen," the authors write.
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.